The new Alzheimer's drug Lecanemab is raising great hopes for people with dementia and their caregivers. But which patient groups and how many affected individuals in Germany meet the criteria for treatment with Lecanemab? This essential question is a significant reason for us to dedicate another issue of our special newsletter to...
In recent weeks, we have informed you in several parts of our special newsletter SCHLAGLICHT – Medications for Dementia about new dementia drugs and challenges in everyday care. You can reread all published issues at any time in our digiDEM Bavaria newsletter archive: https://digidem-bayern.de/newsletter-archiv/. In the seventh and final issue of our special newsletter SCHLAGLICHT – Medications for Dementia, Michael...
In the sixth edition of our special newsletter SCHLAGLICHT – New Medications Against Dementia, Lisa Laininger, research associate at digiDEM Bayern, discusses the publication by Dr. Jeffrey L. Cummings of the University of Nevada Las Vegas and his colleagues, titled Lecanemab: Appropriate Use Recommendations, in the professional journal The Journal of Prevention of Alzheimer’s…
In the fifth edition of our special newsletter, SCHLAGLICHT – New Drugs for Dementia, Anne Keefer, a research associate at digiDEM Bayern, discusses the publication by an international group of researchers led by Prof. Alberto J. Espay of the University of Cincinnati. In the article titled "Recalibrating the Risk-Benefit Profiles of Lecanemab..."
In the fourth edition of our new special newsletter SCHLAGLICHT – New Drugs for Dementia, Florian Weidinger, research associate at digiDEM Bayern, deals with the publication "The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer’s disease: an EADC-EC viewpoint" by the research team led by Professor Linus Jönsson from the Karolinska Institutet in Sweden. In the journal The Lancet…
In the third issue of our new special newsletter "SCHLAGLICHT – New Medications for Dementia," Dr. Nikolas Dietzel, a research associate at digiDEM Bayern, discusses the publication by scientists from Europe, the USA, and Australia, led by Professor Poul F. Høilund-Carlsen from Odense University Hospital in Denmark. In the article titled "Donanemab, another anti-Alzheimer’s…"
In the second part of our new special newsletter, SCHLAGLICHT – New Dementia Medications, Jana Rühl, a research associate at digiDEM Bavaria, discusses the publication by the research team led by Professor Sören Mattke from the University of Southern California. Today, we address the question of whether healthcare systems can even cope with the diagnostic requirements...
SPOTLIGHT – New Medications for Dementia – this is the name of our new series on new active ingredients for the treatment of Alzheimer's disease. We want to shed „spotlight“ on the multifaceted topic of „New Dementia Medications and Challenges for Everyday Care.“ These new medications are intended for people in the early stages of the disease or in the mild phase...
